Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19116931 | 0.91 | TP53 (0.52) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL23665086 | 0.91 | KMT2A (0.56) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18716191 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL20340484 | 0.90 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18199495 | 0.90 | SMN1; SMN2 (0.66) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL18674311 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL22054929 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL24047769 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL607171 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53HPGDALDH1A1KMT2A | |
| SCHEMBL1577892 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | PARABILIS MEDICINES, INC. | 2021-06-17 | — | — | US | disclosed |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-08-07 | — | — | US | disclosed |
| US-10010589-B2 | — | — | 2018-07-03 | — | — | US | disclosed |
| WO-2017091673-A2 | BIVALENT BROMODOMAIN INHIBTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | SMN1; SMN2 3934/4885TP53 609/4885HPGD 2777/4885 |
| US-10913752-B2 | Bivalent bromodomain inhibitors and uses thereof | BRD4, BRD2, BET1 | SMN1; SMN2 3861/4885TP53 605/4885HPGD 2721/4885 |
| US-20200172553-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | SMN1; SMN2 3865/4885TP53 700/4885HPGD 2814/4885 |
| US-10010589-B2 | — | TYMP, MTAP, TUBB6 | SMN1; SMN2 599/4885TP53 325/4885HPGD 1325/4885 |
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | SMN1; SMN2 3934/4885TP53 609/4885HPGD 2777/4885 |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | SMN1; SMN2 1134/4885TP53 581/4885HPGD 4004/4885 |
| US-10039809-B2 | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | SGMS1, SGMS2, PHOSPHO1 | SMN1; SMN2 1134/4885TP53 581/4885HPGD 4004/4885 |
| US-20210179665-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | IAPP, VIP, NGLY1 | SMN1; SMN2 2559/4885TP53 63/4885HPGD 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.